Controversies Regarding Use of Myeloid Growth Factors in Leukemia

View More View Less
  • a From the Division of Medical Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance; and Division of Hematology, University of Washington, Seattle, Washington.
Restricted access

This review focuses on the data supporting the use of myeloid growth factors (MGFs) in patients being treated for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and hairy cell leukemia, for which neutropenia is a common complication of treatment. However, due to the lack of randomized trial data or conflicting results of clinical studies, comprehensive guidelines have been difficult to formulate. Moreover, to date, these diagnoses have not been addressed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MGFs. However, in most cases, the general principles have been included in the applicable NCCN Guidelines for each individual cancer site.

Correspondence: Pamela S. Becker, MD, PhD, Institute for Stem Cell and Regenerative Medicine, 850 Republican Street N415, University of Washingon Campus Box 358056, Seattle, WA 98109. E-mail: pbecker@seattlecca.org
  • 1.

    Griffin JD, Young D, Herrmann F. Effects of recombinant human GM-CSF on the proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986;67:14481453.

    • Search Google Scholar
    • Export Citation
  • 2.

    Vellenga E, Young DC, Wagner K. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987;69:17711776.

    • Search Google Scholar
    • Export Citation
  • 3.

    Miyauchi J, Kelleher CA, Yang Y. The effects of three recombinant growth factors, IL-3, GM-CSF and G-CSF on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 1987;70:657663.

    • Search Google Scholar
    • Export Citation
  • 4.

    Motoji T, Takanashi M, Fuchinoue M. Effect of recombinant GM-CSF and recombinant G-CSF on colony formation of blast progenitors in acute myeloblastic leukemia. Exp Hematol 1989;17:5660.

    • Search Google Scholar
    • Export Citation
  • 5.

    Thomas X, Fenaux P, Dombret H. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomize placebo-controlled trial (EMA91 trial). Leukemia 1999;13:12141220.

    • Search Google Scholar
    • Export Citation
  • 6.

    Bhalla K, Birkhofer M, Arlin Z. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988;2:810813.

    • Search Google Scholar
    • Export Citation
  • 7.

    Miyauchi J, Kelleher CA, Wang C. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989;73:12721278.

    • Search Google Scholar
    • Export Citation
  • 8.

    Tanaka M. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leuk Res 1993;17:585592.

    • Search Google Scholar
    • Export Citation
  • 9.

    Padron E, Painter JS, Kunigal S. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 2013;121:50685077.

    • Search Google Scholar
    • Export Citation
  • 10.

    Nomdedeu M, Lara-Castillo MC, Etxabe A. Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. Cancer Cell Int 2015;15:122.

    • Search Google Scholar
    • Export Citation
  • 11.

    Shen ZH, Zeng DF, Kong PY. AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds. Blood Cells Mol Dis 2016;59:1624.

    • Search Google Scholar
    • Export Citation
  • 12.

    Amgen, Inc. Neupogen [filgrastim]. Available at: http://www.neupogenhcp.com/. Accessed October 26, 2017.

  • 13.

    Sierra J, Szer J, Kassis J. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 2008;8:195.

    • Search Google Scholar
    • Export Citation
  • 14.

    LEUKINE [package insert]. Bridgewater, NJ: sanofi-aventis; 2013.

  • 15.

    Duval C, Boucher S, Moulin JC. Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim. Anticancer Res 2014;34:67476748.

  • 16.

    Heil G, Hoelzer D, Sanz MA. Long-term survival data from a phase 3 study of filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 2006;20:404409.

    • Search Google Scholar
    • Export Citation
  • 17.

    Pabst T, Vellenga E, van Putten W. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012;119:53675373.

    • Search Google Scholar
    • Export Citation
  • 18.

    Löwenberg B, van Putten W, Theobald M. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743752.

    • Search Google Scholar
    • Export Citation
  • 19.

    Ohno R, Naoe T, Kanamaru A. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994;83:20862092.

    • Search Google Scholar
    • Export Citation
  • 20.

    Rowe JM, Andersen JW, Mazza JJ. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457462.

    • Search Google Scholar
    • Export Citation
  • 21.

    Zittoun R, Suciu S, Mandelli F. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996;14:21502159.

    • Search Google Scholar
    • Export Citation
  • 22.

    Löwenberg B, Suciu S, Archimbaud E. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997;90:29522961.

    • Search Google Scholar
    • Export Citation
  • 23.

    Witz F, Sadoun A, Perrin MC. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood 1998;91:27222730.

    • Search Google Scholar
    • Export Citation
  • 24.

    Godwin JE, Kopecky KJ, Head DR. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998;91:36073615.

    • Search Google Scholar
    • Export Citation
  • 25.

    Estey EH, Thrall PF, Pierce S. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93:24782484.

    • Search Google Scholar
    • Export Citation
  • 26.

    Harousseau JL, Witz B, Lioure B. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol 2000;18:780787.

    • Search Google Scholar
    • Export Citation
  • 27.

    Rowe JM, Neuberg D, Friedenberg W. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479485.

    • Search Google Scholar
    • Export Citation
  • 28.

    Amadori S, Suciu S, Jehn U. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005;106:2734.

    • Search Google Scholar
    • Export Citation
  • 29.

    Heil G, Hoelzer D, Sanz MA. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997;90:47104718.

    • Search Google Scholar
    • Export Citation
  • 30.

    Thomas X, Raffoux E, Botton SD. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21:453461.

    • Search Google Scholar
    • Export Citation
  • 31.

    Stone RM, Berg DT, George SL. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995;332:16711677.

    • Search Google Scholar
    • Export Citation
  • 32.

    Gurion R, Belnik-Plitman Y, Gafter-Gvili A. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev 2012;6:CD008238.

    • Search Google Scholar
    • Export Citation
  • 33.

    Alonzo TA, Kobrinsky NL, Aledo A. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 2002;24:627635.

    • Search Google Scholar
    • Export Citation
  • 34.

    Creutzig U, Zimmermann M, Lehrnbecher T. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006;24:44994506.

    • Search Google Scholar
    • Export Citation
  • 35.

    Hockings JK, Owolabi DK, Broyles JE, Wheelis SC. Impact of recommended weight-based dosing of granulocyte-colony factors in acute leukemia and stem cell transplant patients. Support Care Cancer 2017;25:18531858.

    • Search Google Scholar
    • Export Citation
  • 36.

    Kang KW, Kim DS, Lee SR. Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. Leuk Res 2017;57:18.

    • Search Google Scholar
    • Export Citation
  • 37.

    O'Donnell MR, Tallman MS, Abboud CN. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 3.2017. J Natl Compr Canc Netw 2017;15:926957.

    • Search Google Scholar
    • Export Citation
  • 38.

    Price TH, Boeckh M, Harrison RW. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood 2015;126:21532161.

    • Search Google Scholar
    • Export Citation
  • 39.

    Brown PA, Advani A, Aoun P. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2017. Accessed July 3, 2017. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 40.

    Advani AS, Sanford B, Luger S. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup trial C10403 (Alliance) [abstract]. Blood 2013;122:Abstract 3903.

    • Search Google Scholar
    • Export Citation
  • 41.

    Thomas DA, O'Brien S, Faderl S. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:38803889.

    • Search Google Scholar
    • Export Citation
  • 42.

    Weiser MA, O'Brien S, Thomas DA. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 2002;94:285291.

    • Search Google Scholar
    • Export Citation
  • 43.

    Giebel S, Thomas X, Hallbook H. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukemia: a joint analysis of five randomised trials on behalf of the EWALL. Eur J Cancer 2012;48:360367.

    • Search Google Scholar
    • Export Citation
  • 44.

    Ottmann OG, Hoelzer D, Gracien E. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995;86:444450.

    • Search Google Scholar
    • Export Citation
  • 45.

    Welte K, Reiter A, Mempel K. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. Blood 1996;87:31433150.

    • Search Google Scholar
    • Export Citation
  • 46.

    Geissler K, Koller E, Hubmann E. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia—a randomized phase-III study. Blood 1997;90:590596.

    • Search Google Scholar
    • Export Citation
  • 47.

    Larson RA, Dodge RK, Linker CA. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998;92:15561564.

    • Search Google Scholar
    • Export Citation
  • 48.

    Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2005;45:274280.

    • Search Google Scholar
    • Export Citation
  • 49.

    Heath JA, Steinherz PG, Altman A. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol 2003;21:16121617.

    • Search Google Scholar
    • Export Citation
  • 50.

    Heim D, Ebnöther M, Meyer-Monard S. G-CSF for imatinib-induced neutropenia. Leukemia 2003;17:805807.

  • 51.

    Akard L, Kantarjian HM, Nicolini FE. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leuk Lymphoma 2016;57:654665.

    • Search Google Scholar
    • Export Citation
  • 52.

    Quintas-Cardama, Kantarjian H, O'Brien S. Granulocyte-colony stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004;100:25922597.

    • Search Google Scholar
    • Export Citation
  • 53.

    Quintas-Cardam A, De Souza Santos FP, Kantarjian H. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009;115:39353943.

    • Search Google Scholar
    • Export Citation
  • 54.

    Gallipoli P, Stobo J, Heaney N. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukemia patients at 5 years follow-up. Br J Haematol 2013;163:674676.

    • Search Google Scholar
    • Export Citation
  • 55.

    Foo J, Drummond MW, Clarkson B. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 2009;5:e1000503.

    • Search Google Scholar
    • Export Citation
  • 56.

    Pallera A, Altman JK, Berman E. NCCN Guidelines Insights: Chronic Myeloid Leukemia. Version 1.2017. J Natl Compr Canc Netw 2016;14:15051512.

    • Search Google Scholar
    • Export Citation
  • 57.

    Grever MR, Abdel-Wahab O, Andritsos LA. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017;129:553560.

    • Search Google Scholar
    • Export Citation
  • 58.

    Cornet E, Delmer A, Feugier P. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukemia. Ann Hematol 2014;93:19771983.

    • Search Google Scholar
    • Export Citation
  • 59.

    Thompson PA, Ravandi F. How I manage patients with hairy cell leukaemia. Br J Haematol 2017;177:543556.

  • 60.

    Crawford J, Becker PS, Armitage J. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 1.2017. Accessed July 3, 2017. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 61.

    Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999;93:24712477.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 303 204 6
PDF Downloads 150 124 8
EPUB Downloads 0 0 0